U.S. Court in California Rejects Whistleblower Action over Alleged 340B Drug Overcharges
- March 22, 2024
A health care provider cannot maintain a qui tam action under the False Claims Act (FCA) alleging AbbVie Inc. and other pharmaceutical manufacturers failed to comply with the drug pricing requirements of the 340B program, the U.S. District Court for the Central District of California held March 18.
ARTICLE TAGS
You must be logged in to access this content.